* ImmunoTherapeutics Inc., of Fargo, N.D., changed its name toEndorex Corp., which stems from the word endothelium, the tissuefrom which the immune system is derived. The company's OTCBulletin Board symbol changed from IMNP to ENDU and thewarrants from IMPU to ENDUU.
* Orquest Inc., of Mountain View, Calif., presented animal data at theAmerican Society of Bone and Mineral Research meeting showingthat its Ossigel fracture treatment resulted in quicker healing timesthan untreated fractures. Ossigel is a bioengineered matrix combiningfibroblast growth factor and hyaluronic acid.
* Seragen Inc., of Hopkinton, Mass., said Sandoz Ltd., of Basel,Switzerland, exercised its option to license certain U.S. and Canadianpatent rights relating to a transplantation treatment. The patentdescribes use of interleukin-2 receptor targeted monoclonalantibodies for treatment of transplant rejection and other autoimmunediseases. Terms were not disclosed.
* Sugen Inc., of Redwood City, Calif., began a Phase I/II trial ofSU101 in patients with refractory disease in prostate, ovarian andnon-small cell lung cancers. SU101 is a small molecule that inhibitsPDGF receptor signaling.
* The Immune Response Corp., of Carlsbad, Calif., said Phase Iresults of a rheumatoid arthritis treatment, published in the Augustedition of the Journal of Rheumatology, showed patients in the open-label study had a decrease in joint swelling. Immune Responsecurrently has the product in a Phase II trial.
* The Liposome Co., of Princeton, N.J., said its board approved theinitiation of development of ELL-12, which may have application forseveral cancers. The liposomal ether lipid was effective in mousetumor models of melanoma, leukemia and lung cancer. The companysaid ELL-12 does not interact directly with DNA and is notmyelosuppressive.
* Carrington Laboratories Inc., of Irving, Texas, will begin inOctober 1996 its second Phase III trial of Aliminase for ulcerativecolitis. The drug is derived from the Aloe vera plant. The pivotalstudy at 30 U.S. medical centers will enroll about 280 patients.
* Immunomedics Inc., of Morris Plains, N.J., received a $670,000Phase II Small Business Innovation Research grant from the NationalInstitutes of Health, in Bethesda, Md., for development of ahumanized monoclonal antibody with a therapeutic isotope fortreatment of non-Hodgkin's lymphoma.
* Vical Inc., of San Diego, entered a collaboration with StanfordUniversity Medical Center in Palo Alto, Calif., for research intodevelopment of a DNA vaccine against B cell lymphoma. Financialterms were not disclosed.
(c) 1997 American Health Consultants. All rights reserved.